Lead Sponsor

Gilead Sciences

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•Meets all of the following conditions:
•* A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)
•* Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF) with ≥ 8% steatosis
•* Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kPa
•* OR
•* A historical liver biopsy consistent with NASH and non-cirrhotic fibrosis
•Platelet count ≥ 100,000/mm\^3
•Creatinine Clearance (CLcr ) as calculated by the Cockcroft-Gault equation ≥ 60 ml/min

•Pregnant or lactating females
•Alanine aminotransferase (ALT) \> 5 x upper limit of the normal range (ULN)
•Other causes of liver disease including autoimmune, viral, and alcoholic liver disease
•Cirrhosis of the liver
•* Prior history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding
•Body mass index (BMI) \< 18 kg/m\^2
•International normalized ratio (INR) \> 1.2 unless on anticoagulant therapy
•Total bilirubin \> 1 x ULN, except with diagnosis of Gilbert's syndrome

Related studies

NCT06318169 · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

NCT05842512 · Nonalcoholic Steatohepatitis (NASH)

NCT06216041 · Nonalcoholic Steatohepatitis (NASH)

NCT04104321 · Nonalcoholic Steatohepatitis (NASH)

NCT06024408 · Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), and more

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis